AllergyTalk

Cough Miniseries – Episode 2: Diagnosing the Patient's Cough

In this, the second of three podcasts focusing on Cough, host Dr. Purvi Parikh discusses diagnosing cough with Dr. Mandel Sher and Dr. Kevin Murphy. They address diagnosing chronic cough in children and adults. Protracted bacterial bronchitis, the role of GERD in cough, and habit cough are also discussed.
This podcast is supported by an educational grant from Merck & Co., Inc.
ACAAI is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced.
Today’s speakers have the following disclosures:
Kevin Murphy, MD Honoraria: AstraZeneca, Genentech, Novartis, Sanofi, Regeneron
Purvi Parikh, MD
Honoraria: AstraZeneca, Takeda, Genentech/Novartis, Aimmune; Contracted research: AstraZeneca
Mandel Sher, MD
Advisory Committee, Consulting Fee: Merck; Speaker, Honorarium: Optinose; Consulting, Fee: NeRRe; Clinical Investigator, Contracted Research: Attenua, Merck, NeRRe

Cough Miniseries – Episode 1: Understanding the Cough Reflex

In this, the first of three podcasts focusing on Cough, host Dr. Purvi Parikh speaks with Dr. Mandel Sher and Dr. Kevin Murphy about the “true” cough reflex, the cough response, and cough hypersensitivity.
This podcast is supported by an educational grant from Merck & Co., Inc.
ACAAI is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced.
Today’s speakers have the following disclosures:
Kevin Murphy, MD Honoraria: AstraZeneca, Genentech, Novartis, Sanofi, Regeneron
Purvi Parikh, MD
Honoraria: AstraZeneca, Takeda, Genentech/Novartis, Aimmune; Contracted research: AstraZeneca
Mandel Sher, MD
Advisory Committee, Consulting Fee: Merck; Speaker, Honorarium: Optinose; Consulting, Fee: NeRRe; Clinical Investigator, Contracted Research: Attenua, Merck, NeRRe

Episode 10: OIT Safety, OR Anaphylaxis, and IT for Cats

For this episode, we will be reviewing three articles from the Nov-Dec 2019 issue of Allergy Watch, a bimonthly publication which provides research summaries to College members from the major journals in allergy and immunology. To subscribe to Allergy Watch, head over to https://college.acaai.org/publications/allergywatch
We’re pleased to introduce CME credit for Allergy Watch episodes of AllergyTalk! For details, head on over to the AllergyTalk webpage at https://college.acaai.org/allergytalk
Article Links:
Oral immunotherapy for peanut allergy (PACE): a systematic review and meta-analysis of efficacy and safety.
Paired acute-baseline serum tryptase levels in perioperative anaphylaxis: An observational study.
Immunization of cats to induce neutralizing antibodies against Fel d 1, the major feline allergen in human subjects.
Please give us feedback, corrections, and suggestions!
Email feedback to: allergytalk@acaai.org
ACAAI is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced.
Today’s speakers have the following disclosures:
Drs. Lee and Kalangara have nothing to disclose.
Dr. Fineman: Speaker: AstraZenca, Boehringer Ingelheim, Shire; Research: Aimmune, DBV, Shire, Regeneron.

Episode 9: Asthma Epidemiology, Diet, and More on MART Therapy

For this episode, we will be reviewing three articles about asthma from the Nov-Dec 2019 issue of Allergy Watch, a bimonthly publication which provides research summaries to College members from the major journals in allergy and immunology. To subscribe to Allergy Watch, head over to https://college.acaai.org/publications/allergywatch
We’re pleased to introduce CME credit for Allergy Watch episodes of AllergyTalk! For details, head on over to the AllergyTalk webpage at https://college.acaai.org/allergytalk
Article Links:
Racial disparities in asthma-related health care use in the National Heart, Lung, and Blood Institute's Severe Asthma Research Program.
Omega-3 and Omega-6 Intake Modifies Asthma Severity and Response to Indoor Air Pollution in Children. 
Controlled Trial of Budesonide-Formoterol as Needed for Mild Asthma. 
Please give us feedback, corrections, and suggestions!
Email feedback to: allergytalk@acaai.org
ACAAI is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced.
Today’s speakers have the following disclosures:
Drs. Lee and Kalangara have nothing to disclose.
Dr. Fineman: Speaker: AstraZenca, Boehringer Ingelheim, Shire; Research: Aimmune, DBV, Shire, Regeneron.

Episode 8 part 2 - How the College Supports Allergists - Practice Management

Welcome to Episode 8, part 2 of Allergy Talk! I sat down with my co-host Stan Fineman, MD, MBA, ACAAI to review the practice management resources from the ACAAI!
If you have a topic you’d like to cover in a future podcast, let us know at allergytalk@acaai.org.
ACAAI is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced.
Today’s speakers have the following disclosures:
Dr. Fineman Speaker: AstraZenca, Boehringer Ingelheim, Shire; Research: Aimmune, DBV, Shire, Regeneron.
Dr. Lee has no relevant disclosures.

Episode 8 - Part 1: How the College Supports Allergists - Education and Advocacy

Welcome to Episode 8 of Allergy Talk, a roundup of the latest in the field of Allergy and Immunology by the American College of Allergy, Asthma, and Immunology!
At the 2019 ACAAI Annual Meeting in Houston, Texas we interviewed the leaders of the College on how the ACAAI helps its members and what to expect for 2020! If you have a topic you’d like to cover in a future podcast, let us know at allergytalk@acaai.org.
ACAAI is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced.
Today’s speakers have the following disclosures:
Dr. Mahr: 
Research / Consultant / Advisory Board / Speaker / Honorarium:
Aimmune, ALK, AZ, Boeringer-Ingelheim, Kaleo, GSK,  Optinose, Sanofi-Genzyme - Regeneron
Dr. Meadows:
Speaker: Regeneron, Pfizer, AZ, GSK, Optinose
Consultant: Aimmune
Dr. Lee:
No relevant disclosures

Episode 7 - Part II: An Interview with Dr. Brian Vickery

We are excited to present a special 2 part episode of Allergytalk! Dr. Brian Vickery, the principal investigator of the PALISADE study that led to the first FDA-approved peanut immunotherapy, joins us to discuss his personal story and his thoughts on the future of food immunotherapy! If you have a topic you’d like to cover in a future podcast, let us know at allergytalk@acaai.org

Episode 7 - Part I: An Interview with Dr. Brian Vickery

We are excited to present a special 2 part episode of Allergytalk! Dr. Brian Vickery, the principal investigator of the PALISADE study that led to the first FDA-approved peanut immunotherapy, joins us to discuss his personal story and his thoughts on the future of food immunotherapy! If you have a topic you’d like to cover in a future podcast, let us know at allergytalk@acaai.org.
 

Episode 6: Telemedicine in allergy/immunology

We are excited to present a special episode of Allergytalk! Dr. Jennifer Shih, MD joins the podcast to discuss the use of telemedicine in allergy/immunology!
 
Please give us feedback, corrections, and suggestions!
If you have a topic you’d like to cover in a future podcast, let us know at  allergytalk@acaai.org
ACAAI is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced.
Today’s speakers have the following disclosures:
Dr. Lee was on an advisory board for Teva.
Dr. Kalangara has received consulting fees from AstraZeneca.
Dr. Shih was on advisory board for Teva and Tekeda.

• Episode 5: Risk Factors for Venom Allergy, Triggers for Adult-onset Asthma and Associations Between Pollution and ED Visits

This is part 2 of our summaries from the July-August 2019 issue of Allergy Watch:
Investigation of the factors that determine the severity of allergic reactions to Hymenoptera venoms
https://www.ncbi.nlm.nih.gov/pubmed/30819281
New-Onset Asthma in Adults: What Does the Trigger History Tell Us?
https://www.ncbi.nlm.nih.gov/pubmed/30240884
Age-Specific Associations of Ozone and Fine Particulate Matter with Respiratory Emergency Department Visits in the United States
https://www.ncbi.nlm.nih.gov/pubmed/30277796
Please give us feedback, corrections, and suggestions!
Email feedback to: allergytalk@acaai.org
ACAAI is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced.
Today’s speakers have the following disclosures:
Dr. Lee was on an advisory board for Teva.
Dr. Kalangara has received consulting fees from AstraZeneca.
Dr. Fineman Speaker: AstraZenca, Boehringer Ingelheim, Shire; Research: Aimmune, DBV, Shire, Regeneron.